Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 7:11:137-142.
doi: 10.2147/RRU.S204507. eCollection 2019.

Impact of tumor cytoreduction in metastatic prostate cancer

Yaya Sow  1 , Ousmane Sow  1 , Boubacar Fall  1 , Babacar Sine  1 , Alioune Sarr  1 , Cyrille Zé Ondo  1 , Babacar Diao  1 , Alain Khassim Ndoye  1 , Mamadou Ba  1
Affiliations

Impact of tumor cytoreduction in metastatic prostate cancer

Yaya Sow et al. Res Rep Urol. .

Abstract

Objective: To assess the impact of tumor cytoreduction on cancer outcomes and patient survival in metastatic prostate cancer. Patients and methods: It is a prospective study spanning a two-year period between October 1st 2015 and March 31st 2017. We enrolled 102 cases of metastatic hormone-sensitive prostate cancer. Fifty-seven (57) patients had exclusively androgen deprivation therapy (ADT) (group 1) and 45 had, in addition, an open prostatectomy or Transurethral resection of the Prostate (group 2). We compared both groups using the total PSA nadir, the time to PSA nadir, the overall survival (OS), and the progression-free survival (PFS). Results: The average nadir PSA was lower for the tumor cytoreduction group (16.8±1.6 ng/mL (0.01-193.5) versus 110.7±17.9 ng/mL (0.01-1379)). Median time to PSA nadir was shorter in patients in the ADT only group (8 months vs 3 months (p=0.025)). The OS was shorter in patients treated with ADT only compared to the tumor cytoreduction group (median 14 months vs 24 months, respectively (p=0.03)). Similarly, tumor cytoreduction had a positive impact on patient progression (median PFS 20 months (group 1) vs 43 months (group 2)). Conclusion: Tumor cytoreduction has a positive impact on the oncological results and the survival of patients under ADT.

Keywords: TURP; androgen suppression; cytoreduction; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Overall survival curve of patients treated with ADT exclusively (group 1 in blue color) and that of patients treated with ADT and cytoreduction (group 2 in green color). Abbreviation: ADT, androgen deprivation therapy
Figure 2
Figure 2
Progression-free survival curve of patients treated with ADT exclusively (group 1 in blue color) and that of patients treated with ADT + cytoreduction (group 2 in green color). Abbreviation: ADT, androgen deprivation therapy.
Figure 3
Figure 3
Overall survival curve of group 1 and 2 patients after disease progression.
See this image and copyright information in PMC

References

    1. Grosclaude P, Belot A, Marliac LD, Remontet L, Leone N, Bossard N. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol. 2015;25:536–542. doi:10.1016/j.purol.2015.04.011 - DOI - PubMed
    1. Fall B, Tengue K, Sow Y, et al. Place of bilateral pulpectomy as a method of androgen suppression therapy in prostate cancer. Prog Urol. 2012;17(6):1027–3. - PubMed
    1. Qin X-J, Ma C-G, Ye D-W, et al. Tumor cytoreduction results in better response to androgen ablation: a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol. 2012;30:145–149. doi:10.1016/j.urolonc.2010.02.010 - DOI - PubMed
    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297. - PubMed
    1. Boccon-Gibod L, Richaud P, Coloby P, et al. First line indications for hormonal therapy in prostate cancer. Prog Urol. 2010;20:109–115. doi:10.1016/j.purol.2009.11.001 - DOI - PubMed